| PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update V López-Ferrando, A Gazzo, X De La Cruz, M Orozco, JL Gelpí Nucleic acids research 45 (W1), W222-W228, 2017 | 179 | 2017 |
| DEOGEN2: prediction and interactive visualization of single amino acid variant deleteriousness in human proteins D Raimondi, I Tanyalcin, J Ferté, A Gazzo, G Orlando, T Lenaerts, ... Nucleic acids research 45 (W1), W201-W206, 2017 | 88 | 2017 |
| DIDA: A curated and annotated digenic diseases database AM Gazzo, D Daneels, E Cilia, M Bonduelle, M Abramowicz, ... Nucleic acids research 44 (D1), D900-D907, 2016 | 82 | 2016 |
| Predicting disease-causing variant combinations S Papadimitriou, A Gazzo, N Versbraegen, C Nachtegael, J Aerts, ... Proceedings of the National Academy of Sciences 116 (24), 11878-11887, 2019 | 78 | 2019 |
| Understanding mutational effects in digenic diseases A Gazzo, D Raimondi, D Daneels, Y Moreau, G Smits, S Van Dooren, ... Nucleic acids research 45 (15), e140-e140, 2017 | 43 | 2017 |
| Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal CarcinomaSynchronous DCIS and Invasive Ductal Carcinoma F Pareja, DN Brown, JY Lee, A Da Cruz Paula, P Selenica, R Bi, ... Clinical Cancer Research 26 (14), 3682-3693, 2020 | 36 | 2020 |
| Multilevel biological characterization of exomic variants at the protein level significantly improves the identification of their deleterious effects D Raimondi, AM Gazzo, M Rooman, T Lenaerts, WF Vranken Bioinformatics 32 (12), 1797-1804, 2016 | 32 | 2016 |
| Cancer-causative mutations occurring in early embryogenesis F Pareja, RN Ptashkin, DN Brown, F Derakhshan, P Selenica, ... Cancer discovery 12 (4), 949-957, 2022 | 10 | 2022 |
| Using game theory and decision decomposition to effectively discern and characterise bi-locus diseases N Versbraegen, A Fouché, C Nachtegael, S Papadimitriou, A Gazzo, ... Artificial intelligence in medicine 99, 101690, 2019 | 10 | 2019 |
| Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch SyndromeBreast Cancer in Patients with Lynch Syndrome CJ Schwartz, EM da Silva, A Marra, AM Gazzo, P Selenica, VK Rai, ... Clinical Cancer Research 28 (2), 404-413, 2022 | 5 | 2022 |
| TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer EM da Silva, P Selenica, M Vahdatinia, F Pareja, A Da Cruz Paula, ... NPJ Breast Cancer 7 (1), 43, 2021 | 5 | 2021 |
| APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas P Selenica, A Marra, NJ Choudhury, A Gazzo, CJ Falcon, J Patel, X Pei, ... Annals of oncology 33 (12), 1284-1295, 2022 | 3 | 2022 |
| Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma TM D'Alfonso, F Pareja, A Da Cruz Paula, M Vahdatinia, A Gazzo, ... The Journal of Pathology: Clinical Research 7 (2), 113-120, 2021 | 3 | 2021 |
| 210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET)+/-CDK 4/6 inhibition (CDK4/6i) in estrogen receptor … A Marra, A Gazzo, A Gupta, P Selenica, EM Da Silva, F Pareja, X Pei, ... Annals of Oncology 33, S632, 2022 | 2 | 2022 |
| Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma CW Ashley, A Da Cruz Paula, L Ferrando, R Gularte‐Mérida, ... Histopathology 79 (2), 176-186, 2021 | 2 | 2021 |
| Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications J Veeraraghavan, FT Liao, T Gordon, P Selenica, S Nanda, L Qin, Y Zhu, ... Cancer Research 82 (12_Supplement), LB517A-LB517A, 2022 | 1 | 2022 |
| Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of … J Veeraraghavan, S Bose, R Mistry, P Selenica, S Nanda, L Qin, A Gazzo, ... Cancer Research 82 (4_Supplement), PD8-06-PD8-06, 2022 | 1 | 2022 |
| Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and … S Bose, R Mistry, CC Liu, S Nanda, L Qin, P Selenica, A Gazzo, Y Zhu, ... Cancer Research 82 (4_Supplement), P4-01-01-P4-01-01, 2022 | 1 | 2022 |
| KIT genetic alterations in breast cancer M Vahdatinia, F Derakhshan, ADC Paula, H Dopeso, A Marra, AM Gazzo, ... Journal of Clinical Pathology, 2022 | | 2022 |
| Cancer Causative Mutations Occurring in Early EmbryogenesisMosaicism in embryogenesis and cancer F Pareja, RN Ptashkin, DN Brown, F Derakhshan, P Selenica, ... Cancer Discovery, 2022 | | 2022 |
